The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma
Authors:
Open Access
- 23 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 8
Abstract
The Human Papilloma Virus (HPV) is an oncogenic virus which is associated with the development of head and neck squamous cell carcinoma (HNSCC), predominantly within the oropharynx. Approximately 25% of oropharyngeal squamous cell carcinoma (OPSCC) cases worldwide are attributable to HPV infection, with an estimated 65% in the United States. Transmission is via exposure during sexual contact, with distinctive anatomical features of the tonsils providing this organ with a predilection for infection by HPV. No premalignant lesion is identifiable on clinical examination, thus no comparative histological features to denote the stages of carcinogenesis for HPV driven HNSCC are identifiable. This is in contrast to HPV-driven cervical carcinoma, making screening a challenge for the head and neck region. However, HPV proffers a favorable prognosis in the head and neck region, with better overall survival rates in contrast to its HPV negative counterparts. This has resulted in extensive research into de-intensifying therapies aiming to minimize the morbidity induced by standard concurrent chemo-radiotherapy without compromising efficacy. Despite the favorable prognosis, cases of recurrence and/or metastasis of HPV positive HNSCC do occur, and are linked with poor outcomes. HPV 16 is the most frequent genotype identified in HNSCC, yet there is limited research to date studying the impact of other HPV genotype with respect to overall survival. A similar situation pertains to genetic aberrations associated in those with HPV positive HNSCC who recur, with only four published studies to date. Somatic mutations in TSC2, BRIP1, NBN, TACC3, NFE2l2, STK11, HRAS, PIK3R1, TP63, and FAT1 have been identified in recurrent HPV positive OPSCC. Finding alternative therapeutic strategies for this young cohort may depend on upfront identification of HPV genotypes and mutations which are linked with worse outcomes, thus ensuring appropriate stratification of treatment regimens.Keywords
This publication has 183 references indexed in Scilit:
- Does HPV type affect outcome in oropharyngeal cancer?Journal of Otolaryngology - Head & Neck Surgery, 2013
- Role of p63 in Development, Tumorigenesis and Cancer ProgressionCancer Microenvironment, 2012
- The Oral Cavity Contains Abundant Known and Novel Human Papillomaviruses From the Betapapillomavirus and Gammapapillomavirus GeneraThe Journal of Infectious Diseases, 2011
- A TACC3/ch‐TOG/clathrin complex stabilises kinetochore fibres by inter‐microtubule bridgingThe EMBO Journal, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortiumInternational Journal of Epidemiology, 2009
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growthBiochemical Journal, 2008
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003